Find Academic Supervisors

• Hematopathology
• Molecular Diagnostics
• Flow Cytometry
• +7 more

Alexa Siddon, MD, is an Assistant Professor in the Department of Laboratory Medicine at Yale School of Medicine, with secondary appointments in Pathology. She serves as Hematopathology Fellowship Director, Director of the Molecular Diagnostics Laboratory, Director of Flow Cytometry, and Associate Director of the Hematology Laboratory. She is also affiliated with the Yale Cancer Center, Clinical Flow Cytometry Laboratory, and the Hematopathology Laboratory at the Veteran Affairs Connecticut Healthcare System. Dr. Siddon's research focuses on hematopathology, particularly myeloid malignancies, acute leukemias, and post-transplant monitoring. Her work integrates molecular diagnostics, flow cytometry, and genomic analysis to improve patient diagnosis and outcomes. She has co-authored over 10 peer-reviewed articles in recent years, frequently collaborating with leading hematologists and pathologists such as Christopher Tormey, Henry Rinder, and Rory Shallis. Her publications reveal a strong trend in translational research, emphasizing the clinical implications of genetic mutations (e.g., TP53, NPM1, IDH1/2), chimerism testing post-transplant, and immunophenotypic characterization of hematologic malignancies. The research spans disciplines including oncology, molecular biology, immunology, and clinical pathology, with a clear focus on precision diagnostics and prognostic modeling. Scientific Awards: ASCP Distinguished Educator Award Paul J. Strandjord Young Investigator Award Donald H. Buchholz Research Prize Dr. Siddon is actively involved in medical education, directing fellowship programs and mentoring trainees. She has no reported grants listed in the text, but her leadership in diagnostic laboratories and active publication record suggest ongoing research funding. She is not part-time, not retired, and remains a current, active faculty member. She is affiliated with multiple research entities including the Cancer Immunology Center, Center for Biomedical Data Science, and the Yale Cancer Center, contributing to interdisciplinary teams focused on hematologic malignancies and diagnostic innovation.

Henry T. GreelyView profile

Professor

• Bioethics
• Neuroscience
• Genetics
• +5 more

Henry T. Greely is the Deane F. and Kate Edelman Johnson Professor of Law and Professor (by courtesy) of Genetics at Stanford University . He serves on multiple administrative and advisory roles, including Director of the Stanford Center for Law and the Biosciences and Chair of the Stanford Center for Biomedical Ethics. His work bridges bioethics , neuroscience , genetics , and public policy , focusing on the ethical, legal, and societal impacts of emerging biosciences. Education: JD from Yale Law School (1977), AB in Political Science from Stanford University (1974) Key Research Areas: Neuroethics (predictive neuroscience, mind-reading, cognitive enhancement) Genetic Ethics (prenatal testing, genomic biobanks, whole genome sequencing) Stem Cell Law (chimeras, regulatory challenges) Affiliations: Bio-X Faculty Wu Tsai Neurosciences Institute Institute for Human-Centered AI His recent publications address AI misuse in biomedicine, human embryo editing, and cross-cultural chimeric research ethics. Awards include AAAS Fellow (2007) and the Richard M. Lyman Award (2013).

Ype P. de JongView profile

Assistant Professor

• Viral Hepatitis
• Hepatology
• Liver Disease
• +7 more

Dr. Ype P. de Jong is an Assistant Professor of Medicine at Weill Cornell Medical College of Cornell University and an Attending Physician at New York-Presbyterian Hospital. He completed his medical and doctoral training at the University of Amsterdam, followed by internal medicine and gastroenterology fellowships at Mount Sinai Hospital, New York. His research focuses on hepatitis virus immune evasion, liver disease modeling, and gene therapy applications. Education M.D., University of Amsterdam Faculty of Medicine (2003) Ph.D., University of Amsterdam (2002) Research Interests Dr. de Jong investigates hepatitis virus persistence mechanisms, develops advanced liver disease models, and explores gene therapy applications for hemophilia and liver conditions. His work bridges clinical hepatology with translational research on viral immune evasion and hepatocyte engineering. Scientific Awards Cum Laude (PhD thesis), University of Amsterdam (2002) Hippocrates Prize (Best Medical Thesis in Netherlands), Leiden University (2003) Appointments Assistant Professor of Medicine, Weill Cornell Medical College Attending Physician, New York-Presbyterian Hospital Visiting Clinical Fellow, The Rockefeller University

Andrew GodwinView profile

Professor

• Molecular Oncology
• Precision Medicine
• Biomarker Discovery
• +3 more

Andrew Godwin is a Professor at the University of Kansas Medical Center , where he serves as the Chancellor’s Distinguished Chair in Biomedical Sciences and Director of Molecular Oncology in the Department of Pathology and Laboratory Medicine. He is also the Deputy Director of the NCI-designated University of Kansas Cancer Center and the Founding Director of the Kansas Institute for Precision Medicine and Biospecimen Shared Resource . Dr. Godwin is a leader in translational research and precision medicine , with a focus on molecular oncology , biomarker discovery , and genomic diagnostics . His work bridges basic and clinical science to improve cancer patient care, particularly in ovarian cancer , Ewing sarcoma , and breast cancer . He has contributed over 230 ovarian cancer-related publications and pioneered studies linking the PI3K/AKT pathway to cancer treatment targets. His research program encompasses liquid biopsies using extracellular vesicles , molecular therapeutics , companion diagnostics , and clinical trial validation . He leads the Biomarker Discovery Laboratory and has secured over $250M in extramural funding , including a $11.4M NIH grant for precision medicine initiatives. His team has developed CELLSEARCH® , the first FDA-cleared test for circulating tumor cells. Notable awards include the Dolph C. Simons, Sr. Higuchi Award (2020), Outstanding Mentorship in Pathology Award (2024), and multiple mentoring accolades from KU. He has mentored over 150 trainees across career stages and leads a multidisciplinary lab with expertise in genomics , proteomics , and bioengineering . Academic Roles: Chancellor’s Distinguished Chair in Biomedical Sciences Director, Molecular Oncology, Pathology and Laboratory Medicine Deputy Director, KU Cancer Center Founding Director, Kansas Institute for Precision Medicine Adjunct Professor, Bioengineering Program, University of Kansas Scientific Awards: KUMC Achievement Award for mentoring postdocs (2014) Chancellor’s Club Award for Research (2018) Dolph C. Simons, Sr. Higuchi Award (2020) KU Excellence in Mentoring Award (2021) Outstanding Mentorship in Pathology (2024) Key Research Themes: Extracellular vesicles as liquid biopsy tools Molecular mechanisms of sarcoma and breast cancer Genomic diagnostics and precision oncology Clinical trial biomarker validation Biospecimen repository leadership

• Hepatocellular Carcinoma
• Liver Cancer Stem Cells
• Adiponectin Signaling
• +6 more

Lionel Hebbard is a Professor in the Department of Molecular and Cellular Biology at James Cook University's College of Medicine and Dentistry. His research spans hepatocellular carcinoma mechanisms, metabolic liver disease, and cancer therapeutics with significant contributions to adiponectin biology and sarcopenia assessment in cardiac surgery. James Cook University (Current) Department of Molecular and Cellular Biology College of Medicine and Dentistry Senior Researcher in Liver Cancer Biology His research focuses on hepatocellular carcinoma pathogenesis , particularly adiponectin signaling pathways and liver cancer stem cells. He investigates non-alcoholic fatty liver disease progression to cancer, metabolic drivers of tumorigenesis, and therapeutic targeting using aptamer-based delivery systems. Recent work explores sarcopenia quantification via CT imaging for cardiac surgery risk prediction, demonstrating clinical translation of his molecular findings. His lab employs advanced techniques including CRISPR screening (TARGET-SL platform), in vitro cancer models, and murine tumor systems. Analysis of his 15 most recent publications reveals strong emphasis on translational liver cancer research (60%), cardiac surgery complications (20%), and emerging biotechnologies (20%). Key trends include adiponectin's dual roles in fibrosis and tumorigenesis, sarcopenia as a surgical biomarker, and aptamer-based targeting of cancer stem cells. His work consistently bridges molecular mechanisms with clinical applications, particularly in hepatocellular carcinoma diagnostics and treatment. He mentors multiple doctoral students and early-career researchers including Rhys Gillman and Miriam Wankell. His research is supported by continuous funding from Australian NHMRC and international collaborations with George Jacob (Westmead Institute), Qiao Liang (Bentham Books), and Ranscht Barbara (T-cadherin studies). He leads the Hepatic Cancer Biology laboratory focusing on: Liver cancer stem cell characterization Adiponectin receptor signaling in HCC Metabolic drivers of tumor progression Novel drug delivery systems for liver cancer Translational sarcopenia assessment tools

Caroline Arber BarthView profile

Associate Professor

• Hematology
• Immuno-oncology
• Hematopoietic Cell Transplantation
• +7 more

Caroline Arber Barth is an Associate Professor at the University of Lausanne (UNIL), affiliated with the Faculty of Biology and Medicine and the UNIL-CHUV Department of Oncology. She specializes in hematology and immuno-oncology, with a focus on hematopoietic cell transplantation and immunotherapy using genetically modified cells. Her research spans basic, translational, and clinical domains, aiming to improve cancer immunotherapies through adoptive T cell transfer and neoantigen identification. She has pioneered approaches to reduce post-transplant infections and enhance immune reconstitution. Her work targets long-term tumor control while minimizing toxicity in patients. The trends in her publications reflect a strong focus on cellular therapies, particularly CAR-T and TCR-modified T cells, for treating hematological malignancies such as leukemia, lymphoma, and myeloma. Her research integrates molecular engineering, tumor immunology, and clinical applications, emphasizing personalized treatment strategies. Awarded international recognition, her scientific honors include: Dean's Recognition, Stanford University (2002) L'Oréal UNESCO Award for Women in Science (2010) Award from the American Society of Bone Marrow Transplantation (2012) Award from the American Society of Hematology (2013) She has secured major research funding from the NIH, SNSF, Oncosuisse, the Leukemia and Lymphoma Society, and the Cancer Prevention and Research Institute of Texas. She has supervised multiple undergraduate and doctoral students and is actively involved in teaching at both Swiss and U.S. institutions. Her laboratory, based at the Center for Cellular and Gene Therapy (CAGT) during her time in Houston and now at UNIL-CHUV, focuses on developing next-generation cell therapies for cancer.

V Stalin RajView profile

Associate Professor

• Coronaviruses
• Vaccine Development
• Virus Discovery
• +3 more

V Stalin Raj serves as an Associate Professor in the School of Biology at the Indian Institute of Science Education and Research (IISER) Thiruvananthapuram, where he leads research on coronavirus virology and host-pathogen interactions. Previously, he worked as a Scientist at Erasmus Medical Center in Rotterdam, Netherlands (2010-2017) and completed postdoctoral training at the University of Liege, Belgium. Dr. Raj earned his PhD in Biotechnology from the University of Madras in 2007, with thesis research on White Spot Syndrome Virus and Monodon Baculovirus affecting farmed Penaeus monodon. His academic journey includes a BSc in Microbiology (1999) from the University of Madras and an MSc in Biotechnology (2001) from Madurai Kamaraj University. His primary research focuses on coronavirus entry mechanisms, virus-host interactions, and vaccine development. Dr. Raj is particularly known for his work identifying dipeptidyl peptidase 4 (DPP4) as the functional receptor for MERS-CoV, published in Nature (2013). His laboratory investigates how coronaviruses like MERS-CoV and SARS-CoV-2 enter host cells, with emphasis on developing broad-spectrum antivirals and thermostable vaccines suitable for resource-limited settings. Current projects explore natural compounds like EGCG from green tea as potential inhibitors of viral entry across multiple coronavirus strains. Analysis of his recent publication record reveals a strong focus on coronavirus spike protein interactions, neutralizing antibody development, and innovative vaccine platforms. His work spans fundamental virology to translational applications, with increasing emphasis on addressing challenges posed by SARS-CoV-2 variants and the need for broadly reactive coronavirus countermeasures. Scientific Recognition Co-author on multiple high-impact papers in Nature , Science , The Lancet Infectious Diseases , and PNAS Key contributor to identifying DPP4 as the MERS-CoV receptor, a fundamental discovery in coronavirus research Recipient of postdoctoral fellowships at University of Liege and research opportunities at prestigious institutions including Erasmus MC Dr. Raj serves as a journal referee for Emerging Infectious Disease (CDC), Eurosurveillance (ECDC), Journal of Virological Methods, and other prominent virology publications. His research program at IISER Thiruvananthapuram focuses on developing thermostable vaccine platforms and investigating mechanisms of viral entry inhibition, with particular attention to making coronavirus countermeasures accessible in resource-limited settings worldwide.

Eapen K. JacobView profile

Professor

• Transfusion Medicine
• Hematopathology
• Cellular Therapy
• +7 more

Eapen K. Jacob, M.D. is a Professor in the Department of Laboratory Medicine and Pathology at Mayo Clinic in Rochester, Minnesota. He serves as Chair of the Cell Therapy Fellowship Directors Working Group and is actively involved in multiple committees including the MW Cellular Molecular and Bispecifics Steering Committee and the DLMP Clinical Practice Committee. Dr. Jacob received his medical degree from Mayo Medical School in 1998. His extensive training includes fellowships in Transfusion Medicine (2009) and Hematopathology (2007) at Mayo Clinic, a Visiting Clinician position in Transfusion Medicine and Cell Therapy at University of Minnesota Hospital & Clinic (2008), and multiple residency programs in Anatomic and Clinical Pathology, Surgical Pathology, and Ophthalmology at Mayo Clinic. Dr. Jacob's research focuses on Transfusion Medicine, Hematopathology, and Cellular Therapy. His work spans stem cell transplantation, immunohematology, blood banking, and autoimmune hemolytic anemia. He has made significant contributions to understanding cold agglutinin disease, stem cell processing techniques, and CAR-T cell therapy. His research often bridges laboratory medicine with clinical applications, particularly in the context of bone marrow transplantation and blood disorders. Analysis of Dr. Jacob's recent publications reveals a strong focus on cellular therapy, stem cell transplantation, and transfusion medicine. His work addresses critical challenges in cell processing, cryopreservation techniques, and the immunological aspects of transplantation. There is a clear trend toward innovative approaches in CAR-T therapy and the optimization of stem cell transplantation protocols, reflecting the evolving landscape of hematologic malignancy treatment. 2025 DLMP Innovation and Leadership in Education Award Consultant Faculty Nomination 2024 DLMP Innovation and Leadership in Education Award Consultant Faculty Nomination 2020 Innovation Award DLMP Translational Research, Innovation and Test Development Office 2017 Excellence Through Teamwork Award 2005 Best Case Presentation College of American Pathologists National Meeting 2004 Co-Chief Resident 2004 Gastrointestinal Pathology Society Award for clinical research Dr. Jacob plays a significant role in medical education as Chair of the Cell Therapy Fellowship Directors Working Group and has been instrumental in developing fellowship training programs for cellular therapy laboratory directors. His leadership extends to multiple committees focused on cell therapy, transfusion medicine, and laboratory pathology. While specific grant information isn't detailed in the provided text, his extensive publication record and leadership roles suggest substantial research funding support. Dr. Jacob is actively involved with Mayo Clinic's Cellular Therapy Laboratory and Transfusion Medicine services. He collaborates with the Bone Marrow Transplant Program and works closely with the Translational Research, Innovation and Test Development Office (TRITDO). His work impacts patient care through innovations in stem cell processing, blood product management, and cellular therapy applications.

• Oncology
• Neuro-Oncology
• Hematology
• +5 more

Radu O. Minea is an Assistant Professor of Research in Neurological Surgery at the University of Southern California (USC). His research focuses on developing conjugated drug therapies for cancers such as glioblastoma, leukemia, and lymphoma. He specializes in preclinical models to evaluate the efficacy of novel compounds like NEO212, NEO214, and NEO100, which target cancer cells through mechanisms including autophagy inhibition, macrophage differentiation, and enhanced drug delivery to tumor sites. His work bridges molecular oncology, drug design, and translational medicine, with a particular emphasis on overcoming drug resistance in malignant tumors. Key research areas include: Design and testing of conjugated chemotherapeutic agents Mechanisms of drug resistance in gliomas and hematologic malignancies Targeted drug delivery strategies for brain-localized cancers Role of disintegrins and venom-derived peptides in cancer therapy Dr. Minea’s publications highlight innovations in radiosensitization, antiviral cancer therapies, and the application of multi-integrin targeting proteins. His research has implications for improving treatment outcomes in aggressive cancers like glioblastoma and acute myeloid leukemia.

Hisham M. Abdel-AzimView profile

Professor

• Pediatric Hematology/Oncology
• Hematopoietic Cell Transplantation
• Cellular Therapy
• +5 more

Hisham M. Abdel-Azim, MD, MS is a Professor at the School of Medicine with appointments in three divisions: Pediatrics (Hematology/Oncology Division), Medicine, and Basic Sciences (Biochemistry Division) at New York Medical College. His work focuses on pediatric hematopoietic cell transplantation, leukemia research, and cellular therapy development. Dr. Abdel-Azim's research interests span multiple areas of pediatric hematology and oncology: Pediatric Hematopoietic Cell Transplantation and Cellular Therapy Leukemia Biology and Treatment Strategies Stem Cell Transplantation Complications and Management Novel Immunotherapies for Pediatric Cancers Genomic and Molecular Mechanisms in Hematologic Malignancies Transplant-Related Toxicities and Late Effects His recent publications (2024-2025) demonstrate a strong focus on improving outcomes in pediatric hematopoietic cell transplantation, with particular emphasis on managing complications like veno-occlusive disease, optimizing conditioning regimens, and developing novel cellular therapies. His work spans from basic science investigations of molecular mechanisms in leukemia to large multi-center clinical trials through the Children's Oncology Group and other consortia. A significant portion of his research addresses the unique challenges of treating pediatric patients with hematologic malignancies, with publications covering acute lymphoblastic leukemia, acute myeloid leukemia, and severe combined immunodeficiency. Dr. Abdel-Azim serves as Principal Investigator for numerous research projects funded by prestigious organizations including the National Cancer Institute, Children's Oncology Group, National Marrow Donor Program, and industry partners. His work often involves multi-center collaborations across the United States and internationally. He serves as a key investigator in multiple clinical trials focused on: Novel cellular therapies for relapsed/refractory leukemias Optimizing conditioning regimens for hematopoietic cell transplantation Understanding and preventing transplant complications Genomic mechanisms of treatment resistance International registry studies for cellular therapy outcomes

Jonathan S. SerodyView profile

Professor

• Transplantation Immunology
• Graft-versus-Host Disease (GVHD)
• Cellular Therapy
• +7 more

Jonathan S. Serody, MD, serves as the Elizabeth Thomas Professor of Medicine, Microbiology and Immunology at the University of North Carolina at Chapel Hill School of Medicine. He holds multiple leadership positions including Division Chief of Hematology, Associate Director for Translational Science at the UNC Lineberger Comprehensive Cancer Center, and Director of the Cellular Therapy Program. His clinical work focuses on bone marrow and stem cell transplantation, with expertise in leukemia, lymphoma, and malignant hematology. Elizabeth Thomas Professor of Medicine, Microbiology and Immunology (2006-present) Division Chief, Hematology (current) Associate Director for Translational Science, UNC Lineberger Comprehensive Cancer Center Director, Cellular Therapy Program Member, UNC Lineberger Comprehensive Cancer Center Dr. Serody's research program centers on transplantation immunology and cancer immunotherapy development. His laboratory pioneered key discoveries in graft-versus-host disease (GVHD) pathogenesis, including the critical role of chemokines in T-cell migration during GVHD and the function of regulatory T-cells in organ-specific GVHD. More recently, his work has expanded to developing novel immunotherapies for solid tumors, with significant contributions to CAR-T cell therapy enhancement through STING pathway activation and nanoparticle delivery systems. First demonstrated chemokine involvement in GVHD effector phase Discovered CCR5's role in CD4+/CD8+ T-cell differentiation during GVHD Identified Th17 cells as mediators of multi-organ GVHD Developed CAR-T cells from Th17/Tc17 cells combined with STING agonists for solid tumors Discovered NLRP3's role in blocking cancer vaccine efficacy through MDSC recruitment Established B-cell importance in immune checkpoint inhibitor response for breast cancer Dr. Serody's laboratory maintains active collaborations with multiple research groups including the Van Deventer laboratory, CVI, and Dr. Charles Perou's lab. His team has developed advanced imaging techniques for tracking immune cell migration in vivo, including intravital microscopy of eGFP transgenic T-cells. Current clinical trials in his program include testing HER-2/neu vaccine therapy combined with conventional treatment for metastatic breast cancer, with promising early survival data. Awarded the prestigious Hyman L. Battle Distinguished Cancer Research Award in 2023, Dr. Serody maintains editorial roles with Blood (2011-present) and previously with Journal of Clinical Oncology (2009-2012). His leadership extends to serving on the Leukemia and Lymphoma Society TRP Grant Review Group since 2005 and as member of the SPORE Parent Committee. As clinical director of the Advanced Cellular Therapeutics Facility (recently accredited without deficiency citations by the Foundation for the Accreditation of Cellular Therapy), Dr. Serody oversees cutting-edge cellular therapy programs. His educational background includes MD from University of Virginia (1986), residency in Internal Medicine at UNC Chapel Hill (1989), and fellowships in Hematology/Oncology (1994), Infectious Diseases (1992), and Bone Marrow Transplantation at Fred Hutchinson Cancer Research Center (1993).

Juliette TinkerView profile

Professor

• Vaccine Development
• Microbiology
• Immunology
• +5 more

Juliette Tinker, Ph.D., is a Professor in the Department of Biological Sciences at Boise State University (BSU), part of the College of Arts and Sciences. She joined BSU in 2005. Her research focuses on developing mucosal vaccines using non-toxic bacterial enterotoxins as adjuvants, particularly targeting Staphylococcus aureus infections in humans and dairy cattle. Her work aims to reduce antibiotic dependency and improve health outcomes through safe, cost-effective vaccine delivery methods. Dr. Tinker holds a B.S. from Washington University (1994), a Ph.D. from the University of Iowa (2000), and completed postdoctoral training at the University of Colorado Health Sciences Center (2000–2005). She teaches courses including Introductory Microbiology, Pathogenic Microbiology, and Vaccinology. Her research group has engineered chimeric proteins combining Staphylococcus aureus antigens with cholera toxin domains to create vaccines effective against bovine mastitis, a costly condition affecting dairy cattle. This work extends to exploring Salmonella enteriditis toxins and their adjuvant potential. Dr. Tinker’s lab has produced patented vaccines, including a Staphylococcus aureus vaccine recognized with the 2012 Idaho Innovation Award. Her scientific contributions include over 15 peer-reviewed publications, spanning vaccine efficacy, bacterial pathogenesis, and protein engineering. Students mentored include Brad Morris, Connor Richmond, Neha Misra (Ph.D. candidate), and others. Awards for trainees include grants from the International Society of Vaccines (Neha Misra) and poster awards at academic conferences. Dr. Tinker’s lab fosters interdisciplinary collaboration, addressing global health challenges through innovative vaccine strategies.

Ross BathgateView profile

Professor

• Peptide-based Drug Development
• G Protein-coupled Receptor (GPCR) Research
• Structure-based Drug Design
• +3 more

Professor Ross Bathgate is a leading academic at The Florey Institute and an Honorary Professorial Fellow in the Department of Biochemistry and Molecular Biology at the University of Melbourne. His research focuses on neuropeptide interactions with G protein-coupled receptors (GPCRs) for therapeutic drug design, particularly in the relaxin family of peptides . Key Projects: Developing relaxin analogs (B7-33, H3) for antifibrotic and pain treatments, INSL5 analogs for colon motility, and novel GPCR-targeting drugs. Research Impact: Over 250 publications, including Phase III clinical trials for relaxin in acute heart failure. Collaborations: Works with pharmaceutical companies on clinical development of relaxin and other peptide GPCR therapeutics. Notable Article Trends: Focus on structure-based drug design, GPCR dynamics, and translational applications for cardiovascular and gastrointestinal diseases. Labs & Teams: Leads the Neuropeptide Receptor Group at Parkville Campus, University of Melbourne, specializing in peptide-GPCR interactions.

• Transfusion Medicine
• Immunohematology
• Blood Banking
• +5 more

Christopher A. Tormey, MD is a Professor of Laboratory Medicine at Yale University School of Medicine, where he serves as Director of the Transfusion Medicine Service and Director of the Transfusion Medicine Fellowship program. Board certified in Clinical Pathology and Blood Banking/Transfusion Medicine, Dr. Tormey provides clinical services at Yale-New Haven Hospital and VA Connecticut Healthcare System, specializing in transfusion medicine, laboratory hematology, and coagulation. Dr. Tormey's educational background includes a BA in Chemistry from the University of Chicago (2000), an MD from New York Medical College (2004), residency at Yale University School of Medicine (2007), and a Clinical Fellowship in Transfusion Medicine at Yale (2008). His research focuses on critical areas in transfusion medicine including alloimmunization to non-ABO antigens, platelet storage lesions, and optimization of hemostasis assays. Dr. Tormey has made significant contributions to understanding blood group incompatibility, coagulation testing, and platelet function disorders, with numerous publications addressing clinical challenges in transfusion practice. Analysis of Dr. Tormey's recent publications reveals a strong focus on transfusion safety, immunohematology, and clinical management of hematologic disorders. His work spans technical aspects of blood banking, clinical applications in pregnancy and sickle cell disease, and innovative approaches to therapeutic apheresis and stem cell transplantation. Dr. Tormey has received several prestigious awards including: AABB President's Award (2023) ASCP Mastership (2021) Yale School of Medicine Resident Teaching Award (2019) Ellis Benson Award (2015) 40 Under 40 Awardee (2014) As Director of the Transfusion Medicine Fellowship program, Dr. Tormey mentors future specialists in the field. His collaborative research involves extensive work with colleagues at Yale and other institutions, focusing on improving transfusion practices, understanding alloimmunization mechanisms, and optimizing patient care in hematologic conditions. Dr. Tormey is actively involved with the Apheresis/Transfusion Service and Blood Bank at Yale, contributing to clinical service delivery, research initiatives, and educational programs within the Department of Laboratory Medicine.

Maria BakerView profile

Professor

• Hereditary Cancer Syndromes
• Cancer Genetics
• Genetic Counseling
• +5 more

Maria Baker, PhD, MS, LGC is a Professor in the Department of Medicine's Division of Hematology and Oncology at Penn State Cancer Institute, College of Medicine, Penn State University. She developed the Penn State Health Cancer Genetics Program in 1998 and more recently established the Pediatric Cancer Genetics Program in 2016 with support from the Four Diamonds fund. Dr. Baker earned her PhD from Penn State College of Medicine in 1991 and her MS from University of Pittsburgh in 1985. She is a Fellow of the American College of Medical Genetics and Genomics (FACMG). Dr. Baker's research focuses on hereditary cancer syndromes affecting both adult and pediatric populations, with particular emphasis on genetic counseling, testing methodologies, and the ethical, legal, and social implications of cancer predisposition testing. Her work contributes to UN Sustainable Development Goals related to health and well-being. She provides genetic counseling services and risk management strategies including enhanced surveillance, lifestyle changes, chemoprevention, and prophylactic surgery options. Analysis of her recent publications reveals a consistent focus on improving genetic testing accuracy, understanding patient experiences with genetic screening, and addressing professional challenges in genetic counseling. Her work bridges clinical practice with policy development, particularly in cancer genetics. Dean's Award for Excellence in Teaching (2015) Medical Group Dean's List: Extraordinary Patient Satisfaction (2016, 2017, 2018) Honorary award for 99th percentile satisfaction ratings (2018) Dr. Baker has been instrumental in policy development, helping facilitate the passage of genetic counselor licensure in Pennsylvania in 2011 and working at the federal level to secure recognition of genetic counselors by CMS as healthcare providers. She served as Chair of the Penn State Hershey Commission for Women (2013) representing over 7,000 women, and co-chaired the American Association of Medical Colleges Group on Women in Medicine and Science (2016-2018). Her research activities are centered around the Cancer Genetics Program she developed, which serves as a comprehensive resource for individuals concerned about personal or family cancer history.